Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $3.00M | $0.00 | $0.00 | $0.00 | $2.56M | $35.1M |
| Revenue growth | — | — | — | — | — | -100.0% | — | — | — | 1273.2% |
| Operating income | -$24.3M | -$22.2M | -$29.1M | -$51.7M | -$59.9M | -$85.1M | -$87.6M | -$108M | -$36.4M | -$86.9M |
| Operating margin | — | — | — | — | -1995.8% | — | — | — | -1423.6% | -247.4% |
| Net income | -$23.0M | -$22.0M | -$33.3M | -$52.8M | -$62.1M | -$88.7M | -$93.9M | -$101M | -$37.5M | -$79.2M |
| Net margin | — | — | — | — | -2071.0% | — | — | — | -1464.6% | -225.6% |
| EPS (diluted) | -$44.79 | -$54.58 | -$79.15 | -$4.63 | -$3.09 | -$3.99 | -$1.52 | -$17.07 | -$5.59 | -$1.87 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.6M | -$21.3M | -$25.4M | -$48.1M | -$58.8M | -$70.9M | -$77.1M | -$96.5M | -$131M | -$85.6M |
| Capital expenditures | $73.0K | $378K | $0.00 | $174K | $1.36M | $615K | $103K | $60.0K | $326K | $0.00 |
| Free cash flow | -$21.7M | -$21.7M | -$25.4M | -$48.2M | -$60.2M | -$71.5M | -$77.2M | -$96.6M | -$131M | -$85.6M |
| Share buybacks | — | — | — | $0.00 | $0.00 | $2.00M | $0.00 | $0.00 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.2M | $26.7M | $8.13M | $126M | $78.7M | $81.8M | $122M | $99.2M | $55.7M | $217M |
| Total assets | — | $81.3M | $9.94M | $161M | $123M | $117M | $156M | $147M | $146M | $290M |
| Total liabilities | — | $22.5M | $21.6M | $31.5M | $50.1M | $52.8M | $81.5M | $96.2M | $124M | $104M |
| Long-term debt | — | — | $10.0M | $20.0M | $32.5M | $32.5M | $32.5M | $55.0M | $75.0M | $75.0M |
| Shareholders' equity | -$23.1M | -$44.5M | -$77.1M | $129M | $72.8M | $64.4M | $74.1M | $51.1M | $22.1M | $186M |
| Retained earnings | — | -$92.3M | -$79.2M | -$132M | -$194M | -$283M | -$377M | -$478M | -$515M | -$595M |
| Shares (wtd avg diluted) | — | 14.3M | 352K | 16.1M | 20.1M | 25.7M | 63.5M | 5.93M | 6.70M | 42.3M |
Every figure is extracted from X4 Pharmaceuticals, Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.